Vivo Capital Viii, Llc Sells 15,000 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) major shareholder Vivo Capital Viii, Llc sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $0.96, for a total value of $14,400.00. Following the sale, the insider now owns 143,571 shares in the company, valued at approximately $137,828.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Vivo Capital Viii, Llc also recently made the following trade(s):

• On Monday, November 20th, Vivo Capital Viii, Llc sold 54,700 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $50,324.00.

Bolt Biotherapeutics Trading Down 3.2 %

Shares of NASDAQ BOLT traded down $0.03 during mid-day trading on Monday, hitting $0.91. The stock had a trading volume of 184,152 shares, compared to its average volume of 165,264. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.42 and a current ratio of 6.69. Bolt Biotherapeutics, Inc. has a 1 year low of $0.86 and a 1 year high of $2.03. The firm has a market cap of $34.73 million, a P/E ratio of -0.48 and a beta of 0.83. The business has a 50 day moving average price of $1.01 and a two-hundred day moving average price of $1.28.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several hedge funds have recently made changes to their positions in BOLT. Bank of New York Mellon Corp increased its stake in shares of Bolt Biotherapeutics by 13.0% during the first quarter. Bank of New York Mellon Corp now owns 91,293 shares of the company’s stock valued at $249,000 after buying an additional 10,475 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Bolt Biotherapeutics by 226.3% during the 1st quarter. Renaissance Technologies LLC now owns 290,100 shares of the company’s stock worth $795,000 after acquiring an additional 201,200 shares during the period. PDT Partners LLC purchased a new position in shares of Bolt Biotherapeutics during the 1st quarter worth approximately $33,000. Millennium Management LLC purchased a new position in shares of Bolt Biotherapeutics during the 2nd quarter worth approximately $391,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Bolt Biotherapeutics during the 2nd quarter worth approximately $30,000. 73.56% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on BOLT shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, August 3rd. Stifel Nicolaus decreased their target price on shares of Bolt Biotherapeutics from $7.00 to $6.00 in a research note on Tuesday, August 8th.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.